Stockreport

Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

Nuvectis Pharma, Inc.  (NVCT) 
PDF Cleveland Clinic research provides further positive validation Nuvectis Pharma's* NXP900 cancer-fighting potential, showing enhanced efficacy when combined with AstraZen [Read more]